Drug intelligence / Profile preview

Qidong Yixin Granules

Development stage: Phase 4
Lead developer: Sir Run-Run Shaw Hospital
Modality: Small Molecules
Administration: Oral

Overview

Qidong Yixin Granules is a traditional Chinese medicine (TCM) formulation being investigated for its efficacy and safety in preventing the recurrence of atrial fibrillation (AF) following radiofrequency catheter ablation. Developed and studied by researchers at Sir Run Run Shaw Hospital, the treatment aims to reduce AF recurrence rates within one year post-procedure. While the exact molecular mechanism is often complex in TCM, it is typically used to address underlying cardiovascular conditions and promote heart health. Current clinical research includes a Phase 4 multicenter trial evaluating its impact on AF recurrence and exploring potential omics-based mechanisms.

Other names: Qi Dong Yi Xin GranulesQidong Yixin Granule

Beyond the preview

Go deeper on Qidong Yixin Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qidong Yixin Granules.

Explore the full profile